Sumitomo Pharma Stock Slides After Short-Seller Alleges ¥165 Billion Financial Misstatement

Sumitomo Pharmaceutical stock fell 3.7% to ¥1,224 on Tuesday after a report from short-seller Gotham City Research accused the company of significant accounting irregularities. The allegations added to existing investor concerns over a weakening earnings forecast and broader market headwinds.

Short-Seller Allegations

The report from Gotham City Research alleges that Sumitomo Pharmaceutical misstated its fiscal 2025 financial statements by as much as ¥165 billion (approximately $1.05 billion). The short-seller claims the company artificially inflated profits through the manipulation of trade receivables.

Gotham City highlighted a specific discrepancy involving a ¥48 billion dividend from Sumitomo's Swiss subsidiary, which was announced in March 2026, just weeks before the parent company's own financial disclosures. The report also named sister company Sumitomo Chemical.

Weakening Financial Outlook

The short-seller attack comes at a time when Sumitomo's financial performance was already under scrutiny. The company's first-quarter results for fiscal 2027, released on July 31, showed that operating profit had declined by 10.8% year-over-year.

Ad

While the company reported a headline net profit gain, this was primarily attributed to foreign exchange effects rather than core operational strength. Furthermore, management's guidance for the first half of the fiscal year pointed to a steep contraction in profits, leaving investors uncertain about the near-term trajectory even before the Gotham City report was published.

Broader Market Headwinds

The broader Tokyo market provided no support for the stock. The Nikkei 225 index was under significant pressure on Tuesday following confirmation of a joint Japan-U.S. currency market intervention that caused the Japanese yen to surge.

A stronger yen is typically negative for Japan's export-oriented sectors, as it makes their goods more expensive overseas and reduces the value of profits earned abroad. This development dragged down the wider market and added to the negative sentiment surrounding Sumitomo's shares.